MyShare
Key factors
| sym | SAVA |
| exch | US |
| MCap | 916.37M |
| Beta | -0.39 |
| EPS | -2.32 |
| Div date | 2012-12-13 |
Yesterday
| sym | SAVA |
| exch | US |
| close | 20.55 |
| 50 Day MA | 21.95 |
| 200 Day MA | 21.33 |
| 52 Week High | 32.1 |
| 52 Week Low | 12.32 |
| Target Price | 99.5 |
| Market Cap Mln | 916.37 |
Share statistics
| Shares Outstanding | 43.24M |
| Shares Float | 40.19M |
| Percent Institutions | 32.71 |
| PercentInsiders | 7.171 |
| SharesShort | 11.78M |
| Short Ratio | 16.67 |
| Shares Short Prior Month | 11.95M |
| Short Percent | 29.30 |
Income
| Gross Profit TTM | -68.0M |
| EBITDA | -104.4M |
| Diluted Eps TTM | -2.32 |
earning
| EPS Estimate Current Quarter | -0.52 |
| EPS Estimate Current Year | -2.14 |
| EPS Estimate Next Year | -0.47 |
| Earnings Share | -2.32 |
Dividend
| Dividend Date | 2017-05-10 |
| Last Split Date | 2017-05-10 |
| Last Split Factor | 1:7 |
business
| Enterprise Value Ebitda | -8.26 |
| Book Value /share | 3.255 |
| Price Book MRQ | 7.158 |
| ReturnOnAssetsTTM | -0.34 |
| ReturnOnEquityTTM | -0.53 |
Sector
| Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry | Pharmaceuticals |
| Gic Sector | Health Care |
| Gic Sub Industry | Pharmaceuticals |
| Industry | Biotechnology |
| Sector | Healthcare |
Codes
| ISIN | US14817C1071 |
| CIK | 1069530 |
| Code | SAVA |
| CUSIP | 14817C107 |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | NASDAQ |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2024-04-19 |
| Home Category | Domestic |
info
| Fiscal Year End | December |
| ForwardPE | 34.01 |
| Full Time Employees | 29.0 |
| IPODate | 2000-07-14 |
| MostRecent Quarter | 2023-12-31 |
Contact
| Name | Cassava Sciences Inc |
| Address | 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731 |
| Country Name | USA |
| Phone | 512 501 2444 |
| Web URL | https://www.cassavasciences.com |
| Logo URL | /img/logos/US/SAVA.png |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.